10 Best Low Risk Stocks to Buy in 2026

7. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 84

AbbVie Inc. (NYSE:ABBV) is one of the best low risk stocks to buy in 2026. On May 5, AbbVie presented 18 abstracts at the 2026 Digestive Disease Week Annual Meeting, highlighting new real-world and clinical trial data for its IBD therapies, Skyrizi (risankizumab) and Rinvoq (upadacitinib). The findings demonstrate the long-term efficacy, safety, and durability of both treatments for patients with Crohn’s disease and ulcerative colitis.

One-year results from the ASPIRE-CD study showed that Skyrizi provided rapid and sustained relief from Crohn’s disease symptoms, improved patient quality of life, and reduced the need for corticosteroids. Additionally, a 24-month real-world claims analysis revealed that Skyrizi had a significantly lower treatment switch rate (14%) compared to alternative biologics like ustekinumab and vedolizumab.

Real-world data for Rinvoq showed that IBD patients who switched to the drug had lower odds of hospitalization and emergency room visits compared to those who simply escalated their existing biologic doses. Furthermore, clinical data indicated that Rinvoq achieved notable endoscopic improvements through 52 weeks in patients with difficult-to-treat perianal fistulizing Crohn’s disease.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.